GE Healthcare Launches Phase III Trial for Using Flurpiridaz 18F Injection to Detect CAD

GE Healthcare has launched a second phase III (AURORA) clinical trial for using Flurpiridaz 18F Injection in positron-emission tomography (PET) myocardial perfusion imaging (MPI), in order to detect coronary artery disease (CAD).

• Source: The Verdict
• 983
• August 6, 2018